文献速递放射性药物与辐射防护心脏核医学

SARS-CoV-2进入受体核成像工具:ACE2选择性放射性肽的分子模型与临床前开发

A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides.
PubMed 文献 · EJNMMI Res · 2023-04-19

本研究开发了三种靶向ACE2的放射性肽(DOTA-DX600、NODAGA-DX600和HBED-CC-DX600),用镓-67标记后,在转染ACE2或ACE的HEK细胞及荷瘤小鼠中进行体外和体内评价。结果显示所有放射性肽均对ACE2具有选择性,其中[67Ga]Ga-HBED-CC-DX600具有最高的摩尔活度(60 MBq/nmol)和最优的靶/非靶比值,肾脏滞留也较低(7.2 ± 2.2% IA/g),是用于无创检测ACE2表达水平的最有前景的候选化合物。

要点

  • 所有放射性肽对ACE2具有选择性,在HEK-ACE2细胞中摄取为36-43%,在HEK-ACE细胞中摄取<0.1%。
  • [67Ga]Ga-HBED-CC-DX600的摩尔活度为60 MBq/nmol,高于其他肽的20 MBq/nmol。
  • [67Ga]Ga-HBED-CC-DX600在注射后3小时的肾脏滞留为7.2 ± 2.2% IA/g,低于DOTA和NODAGA类似物的约24% IA/g。

核心结论

  • 本研究证明所有放射性肽均具有ACE2选择性,[67Ga]Ga-HBED-CC-DX600因其良好的组织分布特征而被认为是最有前景的候选化合物。
  • HBED-CC螯合剂使得67Ga标记能够达到高摩尔活度,这对于获得高信号-背景对比的图像以检测患者中ACE2表达水平至关重要。

研究设计与样本

  • 本研究通过定制合成获得DOTA-DX600、NODAGA-DX600和HBED-CC-DX600,并用镓-67(半衰期=3.26天)作为镓-68(半衰期=68分钟)的替代放射性同位素进行标记。
  • 体外评价使用转染ACE2和ACE的HEK细胞,体内组织分布评估在HEK-ACE2和HEK-ACE荷瘤小鼠中进行,并使用SPECT/CT进行成像研究。

主要发现

  • [67Ga]Ga-HBED-CC-DX600的摩尔活度最高(60 MBq/nmol),其他肽的标记效率较低(20 MBq/nmol)。
  • 放射性肽在生理盐水中24小时内稳定(完整肽>99%)。
  • 所有放射性肽在HEK-ACE2细胞中显示摄取(36-43%),中等ACE2结合亲和力(KD值:83-113 nM),而在HEK-ACE细胞中未观察到摄取(<0.1%)。
  • 注射后3小时,放射性肽在HEK-ACE2荷瘤小鼠中蓄积(11-16% IA/g),而在HEK-ACE荷瘤小鼠中仅见背景信号(<0.5% IA/g)。
  • 注射后3小时,[67Ga]Ga-DOTA-DX600和[67Ga]Ga-NODAGA-DX600的肾脏滞留仍较高(约24% IA/g),而[67Ga]Ga-HBED-CC-DX600的肾脏滞留低得多(7.2 ± 2.2% IA/g)。

关键数值与推荐

  • [67Ga]Ga-HBED-CC-DX600的摩尔活度为60 MBq/nmol,其他肽为20 MBq/nmol。
  • 放射性肽在HEK-ACE2细胞中的摄取为36-43%,KD值为83-113 nM;在HEK-ACE细胞中摄取<0.1%。
  • 注射后3小时,HEK-ACE2荷瘤小鼠中蓄积为11-16% IA/g,HEK-ACE荷瘤小鼠中<0.5% IA/g。
  • 注射后3小时,[67Ga]Ga-DOTA-DX600和[67Ga]Ga-NODAGA-DX600的肾脏滞留约24% IA/g,[67Ga]Ga-HBED-CC-DX600为7.2 ± 2.2% IA/g。

临床怎么用

  • [67Ga]Ga-HBED-CC-DX600因其有利的组织分布特征和高摩尔活度标记能力,被认为是用于无创检测ACE2表达水平的最有前景的候选化合物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The angiotensin converting enzyme-2 (ACE2)-entry receptor of SARS-CoV-2-and its homologue, the angiotensin-converting enzyme (ACE), play a pivotal role in maintaining cardiovascular homeostasis. Potential changes in ACE2 expression levels and dynamics after SARS-CoV-2 infection have been barely investigated. The aim of this study was to develop an ACE2-targeting imaging agent as a noninvasive imaging tool to determine ACE2 regulation. METHODS: DOTA-DX600, NODAGA-DX600 and HBED-CC-DX600 were obtained through custom synthesis and labeled with gallium-67 (T1/2 = 3.26 d) as a surrogate radioisotope for gallium-68 (T1/2 = 68 min). ACE2- and ACE-transfected HEK cells were used for the in vitro evaluation of these radiopeptides. The in vivo tissue distribution profiles of the radiopeptides were assessed in HEK-ACE2 and HEK-ACE xenografted mice and imaging studies were performed using SPECT/CT. RESULTS: The highest molar activity was obtained for [67Ga]Ga-HBED-CC-DX600 (60 MBq/nmol), whereas the labeling efficiency of the other peptides was considerably lower (20 MBq/nmol). The radiopeptides were stable over 24 h in saline (> 99% intact peptide). All radiopeptides showed uptake in HEK-ACE2 cells (36-43%) with moderate ACE2-binding affinity (KD value: 83-113 nM), but no uptake in HEK-ACE cells (< 0.1%) was observed. Accumulation of the radiopeptides was observed in HEK-ACE2 xenografts (11-16% IA/g) at 3 h after injection, but only background signals were seen in HEK-ACE xenografts (< 0.5% IA/g). Renal retention was still high 3 h after injection of [67Ga]Ga-DOTA-DX600 and [67Ga]Ga-NODAGA-DX600 (~ 24% IA/g), but much lower for [67Ga]Ga-HBED-CC-DX600 (7.2 ± 2.2% IA/g). SPECT/CT imaging studies confirmed the most favorable target-to-nontarget ratio for [67Ga]Ga-HBED-CC-DX600. CONCLUSIONS: This study demonstrated ACE2 selectivity for all radiopeptides. [67Ga]Ga-HBED-CC-DX600 was revealed as the most promising candidate due to its favorable tissue distribution profile. Importantly, the HBED-CC chelator enabled 67Ga-labeling at high molar activity, which would be essential to obtain images with high signal-to-background contrast to detect (patho)physiological ACE2 expression levels in patients.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Beyer D, Vaccarin C, Deupi X, et al. A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides. EJNMMI Res. 2023. PMID: 37074529. doi:10.1186/s13550-023-00979-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。